EY Life Sciences
The delivery of personalized healthcare is causing a power shift with new entrants disrupting incumbents. Innovation, productivity and access to patients challenge every link in the life sciences value chain, from RD and product supply to product launch and patient-centric operating models.
EY Life Sciences brings together a worldwide network of 23,000 sector professionals to anticipate trends, identify implications and help clients create competitive advantage in a health outcomes-driven ecosystem.

Resources
- How digital transformation can benefit the entire health care ecosystem
- How ecosystem participation drives more value for life sciences deals
- Bayer’s journey to becoming a preferred partner in clinical trials
- How mRNA medicines might change the drug landscape
- How life sciences CFOs can drive a reimagined capital strategy